Glucagon-like peptide I improved glycemic control in type I diabetes

BMC Endocrine Disorders

Volumn 3, Issue , 2003, Pages

  Behme, Margaret T ^a   Dupré, John ^a   McDonald, Thomas J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN; PANCREAS POLYPEPTIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CAPILLARY BLOOD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; STATISTICAL ANALYSIS; STOMACH EMPTYING;

EID: 1842598583     PISSN: 14726823     EISSN: None     Source Type: Journal    
DOI: 10.1186/1472-6823-3-3     Document Type: Article

References (13)

1. Holst JJ Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes Metab Res Rev 2002, 18:430-441
2. Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA and Bloom SR Glucagon-like peptide-1 (GLP-1) - a trial of treatment in noninsulin-dependent diabetes mellitus European J Clin Invest 1997, 27:533-536
3. Zander M, Madsbad S, Lysgaard J and Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glucose control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2002, 359:824-830
4. Gutniak M, Orskov C, Holst JJ, Ahren B and Efendic S Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N Engl J Med 1992, 326:1316-1322
5. Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P and McDonald TJ Glucagon-like peptide 1 reduces post-prandial glucose excursions in IDDM Diabetes 1995, 44:626-630
6. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ and Nauck MA Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients Diabetes Care 1996, 19:580-586
7. Dupré J, Behme MT, Hramiak IM and McDonald TJ Subcutaneous glucagon-like peptide-1 combined with insulin normalizes postprandial glycemia in IDDM Diabetes Care 1997, 20:381-384
8. Dupré J, Jenner M, Mahon JL, Purdon C, Rodger NW and Stiller CR Endocrine-metabolic function in remission-phase insulin-dependent diabetes mellitus (IDDM) during administration of cyclosporin Diabetes 1991, 40:598-604
9. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ and Rizza RA Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes Diabetes 2001, 50:565-572
10. Kraegen EW, Chisholm DJ and McNamara ME Timing of insulin delivery with meals Horm Metab Res 1981, 13:365-367
11. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S and Holmes D Inhibition of Dipeptidyl Peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 2002, 25:869-875
12. Dupré J, Behme MT and McDonald TJ Exendin-4 reduces glucose excursions after meals in insulin-treated diabetes. Abstract Diabetes 2002, 51(Suppl 2):A84
13. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N and Schmitz O Bedtime administration of NN2211 a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 2002, 51:424-429